578 Shares in Stryker Co. (NYSE:SYK) Acquired by High Falls Advisors Inc

High Falls Advisors Inc purchased a new stake in Stryker Co. (NYSE:SYK) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 578 shares of the medical technology company’s stock, valued at approximately $209,000.

A number of other large investors also recently made changes to their positions in SYK. Resources Management Corp CT ADV increased its stake in Stryker by 3.9% in the third quarter. Resources Management Corp CT ADV now owns 16,661 shares of the medical technology company’s stock valued at $6,019,000 after purchasing an additional 633 shares during the last quarter. M&T Bank Corp grew its holdings in Stryker by 4.6% in the 3rd quarter. M&T Bank Corp now owns 50,820 shares of the medical technology company’s stock valued at $18,359,000 after buying an additional 2,257 shares during the period. Executive Wealth Management LLC acquired a new position in shares of Stryker during the 3rd quarter valued at about $1,569,000. Continuum Advisory LLC lifted its holdings in shares of Stryker by 310.8% during the 3rd quarter. Continuum Advisory LLC now owns 456 shares of the medical technology company’s stock worth $175,000 after acquiring an additional 345 shares during the period. Finally, LRI Investments LLC boosted its position in shares of Stryker by 14.9% in the third quarter. LRI Investments LLC now owns 340 shares of the medical technology company’s stock worth $130,000 after acquiring an additional 44 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the subject of several research analyst reports. Wells Fargo & Company upped their price target on shares of Stryker from $381.00 to $405.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Citigroup increased their target price on Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Evercore ISI boosted their price target on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group upped their price target on Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $398.40.

Stryker Trading Down 1.0 %

NYSE SYK opened at $381.04 on Tuesday. The stock has a market cap of $145.26 billion, a P/E ratio of 40.84, a PEG ratio of 2.90 and a beta of 0.94. The company’s fifty day simple moving average is $371.49 and its 200-day simple moving average is $354.02. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. Stryker Co. has a 52 week low of $285.79 and a 52 week high of $398.20.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.46 EPS. Equities research analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,715,540. This represents a 17.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,781 shares of company stock worth $24,612,275 in the last 90 days. 5.50% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.